Page 10 - Score Test News Today

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 159,951 shares of the medical research company’s stock, valued at approximately $10,846,000. Connor Clark […]

Connor Clark & Lunn Investment Management Ltd. acquired a new position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 159,951 shares of the medical research company’s stock, valued at approximately $10,846,000. Other institutional investors and […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) insider Brian Baranick sold 1,350 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $85.04, for a total value of $114,804.00. Following the transaction, the insider now directly owns 8,871 shares of the company’s stock, valued […]

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 […]

The LI-raised 'Today' correspondent will also require further surgery.

Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Stock analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Exact Sciences in a research report issued to clients and investors on Wednesday, August 2nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $0.83 for the […]

Exact Sciences (NASDAQ:EXAS – Free Report) had its target price increased by Robert W. Baird from $99.00 to $121.00 in a report published on Wednesday, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock. EXAS has been the topic of a number of other reports. Citigroup raised their […]

Exact Sciences (NASDAQ:EXAS – Free Report) had its target price raised by Credit Suisse Group from $75.00 to $90.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. Credit Suisse Group currently has a neutral rating on the medical research company’s stock. Other analysts also recently issued reports about the stock. StockNews.com started […]

Alpha DNA Investment Management LLC acquired a new position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,342 shares of the medical research company’s stock, valued at approximately $1,040,000. Other hedge funds and […]

Achmea Investment Management B.V. raised its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 3,322.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,986 shares of the medical research company’s stock after acquiring an additional 10,665 shares during the […]